eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2024
vol. 20
 
Share:
Send email
Share:
Original paper

The effect of the systemic immune–inflammatory index on the no-reflow phenomenon in patients undergoing saphenous vein intervention

Ahmet Can Cakmak
1
,
İbrahim Kocayigit
2
,
Perihan Varım
3
,
Betül Sarıbıyık Çakmak
2
,
Yusuf Can
2
,
Mehmet Bülent Vatan
2

  1. Department of Cardiology, Sakarya University Education and Research Hospital, Sakarya, Turkey
  2. Department of Cardiology, Faculty of Medicine, University of Sakarya, Sakarya, Turkey
  3. Heart and Arrhythmia Centre, Focus Tıp Merkezi, Sakarya, Turkey
Adv Interv Cardiol 2024; 20, 2 (76): 148–156
DOI: https://doi.org/10.5114/aic.2024.140259
Online publish date: 2024/06/04
Article file
- The effect of the systemic (1).pdf  [0.12 MB]
Get citation
 
 
1. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e652-735.
2. Harskamp RE, Lopes RD, Baisden CE, et al. Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann Surg 2013; 257: 824-33.
3. Lee MS, Park SJ, Kandzari DE, et al. Saphenous vein graft intervention. JACC Cardiovasc Interv 2011; 4: 831-43.
4. Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013; 111: 178-84.
5. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004; 109: 1121-6.
6. Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 2007; 99: 442-5.
7. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014; 20: 6212-22.
8. Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int 2020; 20: 499.
9. Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal 2021; 35: e23964.
10. Candemir M, Kiziltunç E, Nurkoç S, Şahinarslan A. Relationship between systemic immune- inflammation index (SII) and the severity of stable coronary artery disease. Angiology 2021; 72: 575-81.
11. Oztürk R, Inan D, Güngor B. Systemic immune-inflammation index is a predictor of contrast induced nephropathy in patients with ST-segment elevation myocardial infarction. Angiology 2022; 73: 125-31.
12. Tang Y, Zeng X, Feng Y, et al. Association of systemic immune inflammation index with short-term mortality of congestive heart failure: a retrospective cohort study. Front Cardiovasc Med 2021; 8: 753133.
13. Selcuk M, Cinar T, Saylik F, et al. Predictive value of systemic immune inflammation index for postoperative atrial fibrillation in patients undergoing isolated coronary artery bypass grafting. Medeni Med J 2021; 36: 318-24.
14. Tosu AR, Kalyoncuoglu M, Biter HI, et al. Prognostic value of systemic immune-inflammation index for major adverse cardiac events and mortality in severe aortic stenosis patients after TAVI. Medicina 2021; 57: 588.
15. Vatan MB, Cakmak AC, Agac S, et al. The systemic immune-inflammation index predicts impaired myocardial perfusion and short-term mortality in ST-segment elevation myocardial infarction patients. Angiology 2023; 74: 365-73.
16. Lesiak M, Urbanowicz TK, Olasińska-Wiśniewska A, et al. Neutrophil and lymphocyte count as predictors of the location of calcific coronary lesions in patients treated with rotational atherectomy. Adv Interv Cardiol 2023; 19: 343-50.
17. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018; 138: e618-51.
18. Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol 2010; 22: 6B-14B.
19. Salinas P, Jimenez-Valero S, Moreno R, et al. Update in pharmacological management of coronary no-reflow phenomenon. Cardiovasc Hematol Agents Med Chem 2012; 10: 256-64.
20. TIMI study group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312: 932-6.
21. Van’t Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle myocardial infarction study group. Circulation 1998; 97: 2302-6.
22. Henriques JP, Zijlstra F, Van’t Hof AW, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003; 107: 2115-9.
23. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-92.
24. Zhang Q, Hu M, Sun J, Ma S. The combination of neutrophil-to-lymphocyte ratio and platelet correlation parameters in predicting the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Scand Cardiovasc J 2020; 54: 352-7.
25. Gürbak İ, Panç C, Şahin AA, et al. CHA2DS2- VASc score as a predictor of no-reflow phenomenon after saphenous vein graft percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Cardiol Pol 2020; 78: 1129-36.
26. Hashemi-Jazi M, Hosseini SM, Gholamrezaei A. Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 2017; 13: 221-9.
27. Ozen Y, Bilal Ozbay M. Assessment of systemic immune-inflammation index as an independent surrogate biomarker of no-reflow phenomenon in acute coronary syndrome patients with coronary artery bypass grafting undergoing percutaneous coronary intervention of saphenous vein graft. Eur Rev Med Pharmacol Sci 2023; 27: 2394-403.
28. Shoaib A, Kinnaird T, Curzen N, et al. Outcomes following percutaneous coronary intervention in saphenous vein grafts with and without embolic protection devices. JACC: Cardiovasc Interv 2019; 12: 2286-95.
29. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79: e21-129.
30. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001; 22: 729-39.
31. Siminiak T, Flores NA, Sheridan DJ. Neutrophil interactions with endothelium and platelets: possible role in the development of cardiovascular injury. Eur Heart J 1995; 16: 160-70.
32. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010; 47: 2170-5.
33. Srikanth S, Ambrose JA. Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI. Curr Cardiol Rev 2012; 8: 168-76.
34. Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45: 1638-43.
35. Onsrud M. Influence of in vivo hydrocortisone on some human blood leucocyte sub-populations II. Effects on T cell-monocyte cooperation. Acta Pathol Microbiol Scand 1981; 89: 321-7.
36. Le Tulzo Y, Pangault C, Gacouin A, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002; 18: 487-94.
37. Sen N, Afsar B, Ozcan F, et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 2013; 228: 203-10.
38. Toprak C, Tabakci MM, Simsek Z, et al. Platelet/lymphocyte ratio was associated with impaired myocardial perfusion and both in-hospital and long-term adverse outcome in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Adv Interv Cardiol 2015; 11: 288-97.
39. Kocas C, Abaci O, Arslan S, et al. The association of neutrophil to lymphocyte ratio and TIMI frame count in primary percutaneous coronary intervention. Minerva Cardioangiol 2019; 67: 471-4.
40. Vakili H, Shirazi M, Charkhkar M, et al. Correlation of platelet- to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with thrombolysis in myocardial infarction frame count in ST-segment elevation myocardial infarction. Eur J Clin Invest 2017; 47: 322-7.
41. Zhao B, Li J, Luo X, et al. The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: after primary percutaneous coronary intervention. Tex Heart Inst J 2011; 38: 516-22.
42. Huang J, Zhang Q, Wang R, et al. Systemic immune inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. Med Sci Monit 2019; 25: 9690-701.
43. Gur DO, Efe MM, Alpsoy S, et al. Systemic immune-inflammatory index as a determinant of atherosclerotic burden and high-risk patients with acute coronary syndromes. Arq Bras Cardiol 2022; 119: 382-90.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.